FMP
Kymera Therapeutics, Inc.
KYMR
NASDAQ
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
34.37 USD
0.92 (2.68%)
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
38.23M
52.17M
32.41M
24.09M
41.27M
26.2M
22.32M
19.01M
16.2M
13.8M
1.38
2.97
2.06
1.73
2.99
2.23
2.23
2.23
2.23
445.9M
258.5M
193.03M
199.72M
147.77M
160.43M
136.68M
116.44M
99.2M
84.51M
16.14
14.7
12.29
14.38
10.71
13.64
13.64
13.64
13.64
534.51M
364.68M
421.48M
363.15M
276.42M
265.98M
226.6M
193.05M
164.47M
140.12M
19.35
20.74
26.84
26.15
20.03
22.62
22.62
22.62
22.62
400.98M
296.77M
251.07M
287.61M
249.88M
202.7M
172.69M
147.12M
125.34M
106.78M
14.52
16.87
15.99
20.71
18.1
17.24
17.24
17.24
17.24
-33.71M
-36.27M
-27.65M
-23.55M
-23.6M
-19.87M
-16.93M
-14.42M
-12.29M
-10.47M
-1.22
-2.06
-1.76
-1.7
-1.71
-1.69
-1.69
-1.69
-1.69